ExThera Medical Corporation: Blood Purification and Pathogen Reduction Treatment for Sepsis and COVID-19 Set for Pan-European Distribution Launch
ExThera Medical s Seraph 100 Microbind Affinity Filter (Seraph 100) is now being distributed in Europe by Fresenius Medical Care, the world s leading provider of products and services for individuals with renal diseases. Since 2019 the therapeutic device has been used throughout the continent under a CE Mark for the treatment of bloodstream infections. In the United States Seraph is being used to treat critically-ill COVID-19 patients. The two companies signed a co-marketing and distribution agreement earlier this year.
Physicians across Europe and the United States have observed improvements in mortality and reduced use of vasopressors with use of the Seraph 100.
(2)
PHILADELPHIA, PA / ACCESSWIRE / December 10, 2020 / Tridiuum, the nation s premier provider of digital behavioral health solutions, today announced it has been selected for a first-of-its-kind behavioral health pilot with Fresenius Medical Care North America (FMCNA), the nation s leading provider of kidney care products and services. The pilot, which will begin with dialysis centers in the North Georgia area, will integrate the Tridiuum ONE platform into the company s clinical workflow for early identification of patients behavioral health issues.
Studies show that behavioral health conditions, including depression and anxiety disorders, are prevalent in patients with chronic kidney disease (CKD). These conditions often impact patients overall quality of life and can lead to longer hospitalizations and higher mortality. Undiagnosed behavioral conditions can directly affect a patient s adherence to lifesaving treatment and medication regimens.